Clinical effects of direct hemoperfusion using a polymyxin-B immobilized column in solid organ transplanted patients with signs of severe sepsis and septic shock. A pilot study

International Journal of Artificial Organs

Volumn 30, Issue 10, 2007, Pages 915-922

  Ruberto, F ^a   Pugliese, F ^a   D'Alio, A ^a   Martelli, S ^a   Bruno, K ^a   Marcellino, V ^a   Summonti, D ^a   Celli, P ^a   Perrella, S ^a   Cappannoli, A ^a   Pietropaoli, C ^a   Tosi, A ^a   Diana, B ^a   Novelli, G ^a   Rossi, M ^a   Ginanni Corradini, S ^a   Ferretti, G ^a   Berloco, P B ^a   Pietropaoli, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Endotoxin; Hemoperfusion; Kidney transplantation; Liver transplantation; Polymyxin B; Sepsis; Septic shock; Solid organ transplantation

Indexed keywords

ANTIBIOTICS; BLOOD PRESSURE; DRUG DOSAGE;

CLINICAL EFFECTS; ENDOTOXIN; GRAM-NEGATIVE BACTERIA; HEMOPERFUSION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; POLYMYXIN B; SEPSIS; SEPTIC SHOCKS; SOLID ORGAN TRANSPLANTATION;

BACTERIA;

ANTIBIOTIC AGENT; CYCLOSPORIN; DOBUTAMINE; HYPERTENSIVE FACTOR; INOTROPIC AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; NORADRENALIN; OXYGEN; POLYMYXIN B; TACROLIMUS;

ABDOMINAL ABSCESS; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTERIAL OXYGEN TENSION; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM IDENTIFICATION; BILIARY TRACT INFECTION; BODY TEMPERATURE; BRADYPNEA; CENTRAL VENOUS PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEBRIDEMENT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT INFECTION; GRAFT REJECTION; GRAM NEGATIVE BACTERIUM; HEART RATE; HEMODYNAMIC PARAMETERS; HEMOPERFUSION; HUMAN; HYPOTENSION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MEAN ARTERIAL PRESSURE; MEDICAL ASSESSMENT; ORGAN TRANSPLANTATION; PATIENT MONITORING; PILOT STUDY; POSITIVE END EXPIRATORY PRESSURE; SEPSIS; SEPTIC SHOCK; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 38149056438     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880703001009     Document Type: Article

References (26)

1. Alberti C, Brun-Buissoh C, Burchardi H, Martin C, et al. Epidemiology of sepsis and infections in ICU patients from an international multicentre cohort study. Intensive Care Med 2002; 28: 108-21.
2. Moreno A, Mensa J, Almeda M, et al. 138 episodes of bacteremia or fungemia in patients with solid organ (renal or hepatic) transplantation. Med Clin (Barc) 1994; 103: 161-4.
3. Wagener MM, Yu VL. Bacteremia in transplant recipients: a prospective study of demographics, etiologic agents, risk factors and outcomes. Am J Infect Control 1992; 20: 239-47.
4. Candel FJ, Grima E, Matesanz M, Cervera C, Soto G, Almela M, Martinez JA, Navasa M, Cofan F, Ricart MJ, Perez-Villa F, Moreno A. Bacteremia and septic shock after solid-organ transplantation. Transplant Proc 2005; 37: 4097-9.
5. Lichtenstern C, Schmidt J, Knaebel HP, Martin E, Buchler MW, Weigand MA. Postoperative Bacterial/Fungal Infections: A Challenging Problem in Critically III Patients after Abdominal Surgery. Digest Surg 2007; 24: 1-11.
6. Wallace WC, Cinat ME, Nastanski F, Gornick WB, Wilson SE. New epidemiology for postoperative nosocomial infections. Am Surg 2000; 66: 874-8.
7. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. JAMA 1995; 27; 274: 968-74.
8. Singh N, Wagener MM, Obman A, Cacciarelli TV, de Vera ME, Gayowski T. Bacteremias in liver transplant recipients: shift toward gram-negative bacteria as predominant pathogens. Liver Transpl 2004; 10: 844-9.
9. Bellorno R, Honore PM, Matson J, Ronco C, Winchester J. Extracorporeal blood treatment methods in SIRS/sepsis. Int J Artif Organs 2005; 28: 450-8.
10. Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 2002; 28: 1434-9.
11. Bellomo R, Baldwin I, Ronco C. Extracorporeal blood purification therapy for sepsis and systemic inflammation: its biological rationale. Contrib Nephrol 2001; 132: 367-74.
12. Bellomo R, Baldwin I, Ronco C. High-volume hemofiltration. Contrib Nephrol 2001; 132: 375-82.
13. Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 2003; 7: 108-14.
14. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
15. Bernard GR. Quantification of organ dysfunction: seeking standardization. Crit Care Med 1998; 26: 1767-8.
16. Angele MK, Loehe F, Faist E. Immunomodulation during sepsis in organ transplanted children. Minerva Pediatr 2005; 57: 259-68.
17. Vincent JL, Laterre PF, Cohen J, Burchardi H, Bruining H, Lerma FA, Wittebole X, De Backer D, Brett S, Marzo D, Nakamura H, John S. A pilot-controlled study of a Polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005; 23: 400-5.
18. Nakamura T, Matsuda T, Suzuki Y, Shoji H, Koide H. Polymyxin B-Immobilized Fiber Hemoperfusion in Patients with Sepsis. Dial Transplant 2003, 32: 602-07
19. Yonekawa C, Nakae H, Tajimi K, Asanuma Y. Combining continuous endotoxin aphaeresis and continuous hemodiafiltration in the treatment of patients with septic multiple organ dysfunction syndrome. Ther Apher Dial 2006; 10: 19-24.
20. Kushi H, Miki T, Okamaoto K, Nakahara J, Saito T, Tanjoh K. Early hemoperfusion with an immobilized Polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Crit Care 2005; 9: R653-61.
21. Tojimbara T, Sato S, Nakajima I, Fuchinoue S, Akiba T, Teraoka S. Polymyxin B-immobilized fiber hemoperfusion after emergency surgery in patients with chronic renal failure. Ther Apher Dial 2004; 8: 286-92.
22. Wang Y, Liu Y, Sarker KP, Nakashima M, Serizawa T, Kishida A, Akashi M, Nakata M, Kitajima I, Maruyama I. Polymyxin B binds anandamide and inhibits its cytotoxic effect. FEBS Lett 2000; 470: 151-5.
23. Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet and macrophage derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998; 12: 1035-44.
24. Kohro S, Imaizumi H, Yamakage M, Masuda Y, Namiki A, Asai Y, Maruyama I. Anandamide absorption by direct hemoperfusion with Polymyxin B-immobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis. J Anesth 2006; 20: 11-6.
25. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med 2001; 29: 1303-10.
26. Sands KE, Bates DW. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997; 278: 234-40.